AUS
NZ
UK
CA
USA
IND
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape
Highlights,Indivior (LON:INDV) will cancel its secondary listing on the London Stock Exchange by the end of July.,The decision follows a decline in share price and a strategic focus on the Nasdaq.,The company cited cost reduction and lower liquidity in Lo...
- June 02, 2025 11:12 AM BST
- Team Kalkine Media
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing
Highlights,Indivior to delist from the London Stock Exchange while maintaining its primary listing on the Nasdaq,The pharmaceutical company generates the majority of its revenue from the United States,Delisting expected to take place in July following str...
- June 02, 2025 10:59 AM BST
- Team Kalkine Media
Kalkine : FTSE 100 Pharmaceutical Firm Indivior to Exit London Stock Exchange Amid US Market Focus
Highlights,Indivior (LON:INDV) plans to delist from the London Stock Exchange in July, citing alignment with its US-focused revenue and operations.,The pharmaceutical firm moved its primary listing to the Nasdaq last year, citing higher liquidity and redu...
- June 02, 2025 10:50 AM BST
- Team Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq
Highlights,Indivior PLC (LON:INDV) has announced the cancellation of its secondary listing on the London Stock Exchange.,The company will maintain its primary listing on the Nasdaq Stock Market in the United States.,The decision follows an evaluation of t...
- June 02, 2025 10:46 AM BST
- Team Kalkine Media